Drug intelligence / Profile preview

runihol

Development stage: Phase 2
Lead developer: POLYSAN
Modality: Small Molecules
Administration: Oral

Overview

Runihol is an investigational oral drug studied primarily for the treatment of nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome. It has also been evaluated in preclinical models for its effects on liver injury, where it was compared to S-adenosyl-L-methionine (SAM). The precise mechanism of action is not fully described in available sources, but clinical studies have assessed its impact on hepatic function and cytolysis syndromes. Runihol is administered orally as tablets[1][3].

Brand names: runihol
Other names: runihol

Beyond the preview

Go deeper on runihol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on runihol.

Explore the full profile